Join our daily newsletter At The Bell to receive exclusive market insights
- Archer Materials (AXE) has filed a patent application for its graphene biosensor technology
- The company did so under the Patent Cooperation Treaty, which will allow for international patent protection
- Biosensors are used in the medical industry to optimise patient care and fast track disease detection
- Archer is developing a unique graphene-based technology which can be used to manufacture biosensors
- Moving forward, Archer will seek to establish partnerships with highly resourced biotech companies
- Despite the news, shares are down 3.8 per cent and trading for 19 cents each
Archer Materials (AXE) has filed a patent application under the Patent Cooperation Treaty (PCT) for its graphene biosensor technology intellectual property.
The international patent will allow Archer to commercialise its technology which has the potential to solve selectivity and detection challenges in biosensing.
The PCT will also allow Archer to decide which countries to have patent protection in and will allow for international protection which can last for up to 20 years.
“Filing an international patent application represents the first step in the commercialisation of the company’s graphene biosensor technology,” CEO Dr Mohammad Choucair said.
Dr Choucair believes this technology “has the potential to positively disrupt the emerging Medtech industry”
Biosensors are used in medical testing and diagnostics and can reduce patient wait times.
The global biosensor market revenue is expected to grow to US$27 billion (A$40.1 billion) by 2022, due to ageing populations in North America, Europe and Asia.
Archer is developing a unique graphene-based technology that may be the solution to rapid, portable testing for in-vitro diagnostics.
Its uniqueness lies in the use of digital manufacturing to print sensitive graphene materials that are integrated into one or more sensors.
The next step in the patent process is the receipt from the World International Patent Organisation which is expected in the next few days.
It intends to commercialise the biosensing technology by seeking partnerships which highly resourced biotech organisations.
Archer is down 3.8 per cent and shares are trading for 19 cents each at 3:24 pm AEDT.
